ENLIVEN THERAPEUTICS, INC. Other Comprehensive Income (Loss), Net of Tax
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Other Comprehensive Income (Loss), Net of Tax of -$1.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$1.52M.
- ENLIVEN THERAPEUTICS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$716.00K.
- ENLIVEN THERAPEUTICS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $398.00K, a 4.46% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was -$161.00K.
- ENLIVEN THERAPEUTICS, INC. other comprehensive income (loss), net of tax for fiscal 2025 was $279.00K.
- ENLIVEN THERAPEUTICS, INC. other comprehensive income (loss), net of tax for fiscal 2024 was -$86.00K, a 160.99% decline from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $141.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.52M 10-Q · filed 2026-08-05 | -$2.24M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | -$716.00K 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $279.00K 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $398.00K 10-Q · filed 2025-11-12 | $237.00K derived: sum of 2 quarters · filed 2026-08-05 | $166.00K derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$161.00K 10-Q · filed 2026-08-05 | -$232.00K derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$71.00K 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | -$86.00K 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $381.00K 10-Q · filed 2025-11-12 | $295.00K derived: sum of 2 quarters · filed 2025-11-12 | $101.00K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$86.00K 10-Q · filed 2025-11-12 | -$280.00K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | -$194.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $141.00K 10-K · filed 2025-03-13 | |||
| 2023-09-30 | -$36.00K 10-Q · filed 2024-11-13 | -$147.00K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-06-30 | -$111.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |